MARKET

VNRX

VNRX

VOLITIONRX
AMEX

Real-time Quotes | Nasdaq Last Sale

3.920
-0.110
-2.73%
Closed 16:00 03/03 EST
OPEN
4.030
PREV CLOSE
4.030
HIGH
4.079
LOW
3.820
VOLUME
417.20K
TURNOVER
--
52 WEEK HIGH
6.67
52 WEEK LOW
2.220
MARKET CAP
203.35M
P/E (TTM)
-8.9785
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
VNRX: VolitionRx Launched Nu.Q Vet Cancer Screening Test; Silver One Manufacturing Opened; Equity Offering & Cash Grant Provide Over $20 million
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT VolitionRx (NYSE:VNRX) is engaged in multiple epigenetic projects coupled with several corporate initiatives . The company is involved with developing numerous blood-based clinical assays ...
Zacks Small Cap Research · 02/19 11:03
Diamond Equity Research Emerging Growth Invitational Winter 2021 Virtual Conference
Our conferences are open to both institutional and retail investors, allowing all investors to obtain meaningful access to management teams," stated Hunter Diamond, CFA, the CEO of Diamond Equity Research.Investors can register at https://www.
ACCESSWIRE · 02/17 14:00
Proactive news headlines including Alpine 4 Technologies, Aequus Pharmaceuticals, Aurania Resources and VolitionRx
- Alpine 4 Technologies Ltd (OTCQB:ALPP) enters definitive agreements for registered direct offering for gross proceeds of approximately $50M click here
GlobeNewswire · 02/13 02:29
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a ra...
PR Newswire - PRF · 02/12 14:25
Bio-Path, Cancer Genetics leads healthcare gainers; Neovasc, Panbela Therapeutics amomg major losers
Gainers: Bio-Path BPTH +261%, Cancer Genetics (CGIX) +120%, Sundial Growers (SNDL) +31%, Gamida Cell (GMDA) +26%, Clever Leaves (CLVR) +22%.Losers: Neovasc NVCN -28%, Panbela Therapeutics PBLA -24%, Ocugen (OCGN) -19%, Aeterna Zentaris (AEZS) -19%, Volitio...
Seekingalpha · 02/10 16:00
Sector Update: Health Care Stocks Hanging on for Slim Gains
MT Newswires · 02/10 15:55
VolitonRx prices underwritten public offering
VolitonRx ([[VNRX]] -14.8%) priced its underwritten public offering of 3.81M shares for gross proceeds of ~$20M.Volition has granted the underwriter a 30-day option to purchase up to an additional 571,428 shares.Proceeds to be
Seekingalpha · 02/10 14:41
BRIEF-VolitionRx Limited Announces Pricing Of $20 Million Underwritten Public Offering Of Common Stock
reuters.com · 02/10 14:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNRX. Analyze the recent business situations of VOLITIONRX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNRX stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 3.02M
% Owned: 5.83%
Shares Outstanding: 51.87M
TypeInstitutionsShares
Increased
9
101.54K
New
1
802
Decreased
4
84.17K
Sold Out
2
35.57K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.37%
Healthcare Equipment & Supplies
-2.63%
Key Executives
Chairman/Executive Director
Martin Faulkes
Chief Executive Officer/President/Director
Cameron Reynolds
Chief Financial Officer/Treasurer
Terig Hughes
Corporate Executive
Jasmine Kway
Chief Operating Officer
Gaetan Michel
Chief Technology Officer
Mark Eccleston
Chief Scientific Officer
Jacob Micallef
Other
Gael Forterre
Other
Jason Terrell
Secretary
Rodney Rootsaert
Independent Director
Phillip Barnes
Independent Director
Salvatore Butera
Independent Director
Alan Colman
Independent Director
Edward Futcher
Independent Director
Guy Innes
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About VNRX
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Webull offers kinds of VolitionRX Ltd stock information, including AMEX:VNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNRX stock methods without spending real money on the virtual paper trading platform.